🚨Publication Alert🚨
This week's publication is from Dr. Nidal Al-Huniti, President of Clinical Pharmacology at Amador Bioscience.
📃Read it here: https://hubs.la/Q01vb2pl0
The authors of this publication and others applied an agent-based mathematical model (ABM) to explore the role of anti-viral monoclonal antibodies (mAbs) in combination with vaccines in reducing the COVID-19 pandemic burden.
Mathematical modeling is a fast-growing tool to inform decision-making in scenarios where it may not be feasible to prospectively evaluate interventions in concert.
In this case, ABM was used to characterize the individual-level heterogeneity of SARS-CoV-2 transmission in the US population. The model enabled the simulation of various pandemic scenarios including vaccine and mAbs in combination with vaccine. The mAbs were used as active treatment for Treatment-as-Prevention strategy and as passive immunity for post-exposure prophylaxis (PEP).
The results indicated that the use of anti-viral mAbs as treatment and PEP in combination with a vaccination program would substantially reduce SARS-CoV-2 transmission and pandemic burden. This approach can inform public health policies and is applicable to future pandemic preparedness.
